Ventyx Biosciences reported its financial results for the fourth quarter and full year ended December 31, 2024. The company's cash, cash equivalents, and marketable securities balance stood at $252.9 million as of December 31, 2024. This financial position is projected to fund planned operations into at least the second half of 2026.
The company reaffirmed its anticipated clinical milestones for 2025, with topline data readouts expected from multiple Phase 2 studies throughout the year. The Phase 2 biomarker trial of VTX3232 in Parkinson’s disease is on track for completion in the second quarter of 2025. Planning for the next phase of development for VTX3232 in Parkinson's disease has been initiated.
Ventyx also expects to share results from the Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors in the second half of 2025. Additionally, results from the Phase 2 trial of VTX2735 in patients with recurrent pericarditis are anticipated in the second half of 2025, further advancing its NLRP3 inhibitor portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.